Alice Verdelli1*
Alberto Corrà2
Elena Biancamaria Mariotti2
Cristina Aimo2
Valentina Ruffo di Calabria2
Walter Volpi1
Lavinia Quintarelli3
Marzia Caproni3- 1Section of Dermatology, Azienda USL Toscana Centro, Florence, Italy
- 2Section of Dermatology, University of Florence, Florence, Italy
- 3Rare Dermatological Diseases Unit, Department of Health Sciences, Azienda USL Toscana Centro, University of Florence, Florence, Italy
Management of cutaneous lupus erythematosus (CLE) involves a combination of preventive measures, topical and systemic drugs, fairly similar for the different subtypes. Although guidelines exist, to date, no specific drugs have been specifically licensed for CLE. Antimalarials remain the first-line systemic treatment, but many patients do not respond, making refractory lupus a challenge for clinicians. The choice of alternative medication should be based on effectiveness, safety and cost. Most of the available drugs for CLE have been adapted from systemic lupus erythematosus (SLE) treatment but the existing literature is limited to small studies and evidence often lacks. As knowledge of pathogenesis of both CLE and SLE is improving, promising new therapies are emerging. In this review, we discuss the available medications, focusing on the novelties under development for CLE.
Introduction
Cutaneous lupus erythematosus (CLE) is a chronic, autoimmune, inflammatory disease comprising several subtypes, e.g., acute CLE (ACLE), subacute CLE (SCLE), chronic CLE (CCLE) and intermittent CLE (ICLE) (1). CLE can be isolated or associated to a systemic involvement. Up to 70–80% of patients with systemic LE (SLE) develop muco-cutaneous lesions during the course of the disease and up to 25% of patients with systemic LE (SLE) show muco-cutaneous involvement at diagnosis (2, 3). Thus, a systemic involvement should always be assessed at diagnosis and at follow-up (4).
To monitor CLE progression and treatment response, two scores have been validated, e.g., the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) and, more recently, the Revised CLASI (RCLASI), which are able to provide disease activity (CLASI-A) and damage (CLASI-D) in CLE patients (5, 6).
According to current guidelines (7–9), management of CLE involves a combination of topical and systemic drugs, fairly similar for the different subtypes. Although consensus over the treatment and guidelines have been succeeded over the years, to date, no specific drugs have been approved by the Food and Drug Administration (FDA). Most of the medications for CLE have been adapted from SLE treatment but the existing literature is limited to small studies and evidence often lacks. As drugs that have proven to be effective in systemic disease may not be effective in cutaneous disease, the treatment of refractory CLE is particularly challenging, as it is difficult to achieve a consensus on the appropriate progression of treatment beyond first- and second-line treatment options. Moreover, since many of these treatments are immunosuppressants, with possible side effects, a thoughtful approach is mandatory in order to better select the most appropriate drug (10).
General recommendations include sun protection, smoking cessation and vitamin D implementation as well as withdrawal of photosensitizing drugs and avoidance of isomorphic trigger factors (9, 11–13). Female patients are also recommended to avoid hormonal contraception containing estrogens and estrogen replacement therapies. These measures are crucial to prevent refractory CLE. In fact, studies on the photoprotective habits of lupus patients have shown an increased frequency of sunscreen utilization during years (14, 15). However, not all patients with CLE use daily sun protection, not all apply the right dose and not all re-apply sunscreen during the day. Yang et al. found that especially males, patients with dark Fitzpatrick skin types, and patients between the ages of 31–50 use less frequently sun protection than necessary (16). Accordingly, active smoking has been associated with CLE severity, with a lower risk of long-term CLE remission (17). Although it is known that it decreases the efficacy of systemic treatment, the impact of tobacco on the efficacy of antimalarials may be caused by an increase in the severity of the disease more than by resistance in smokers (18).
Topical corticosteroids remain the first-line treatment of all CLE subtypes, both in localized and widespread form (7–9). They should be applied for a short time or intermittently to reduce side effects, such as atrophy, telangiectasia and steroid-induced dermatitis. Alternatively, as first-line or second-line topical treatment, calcineurin inhibitors (0.03% or 0.1% tacrolimus and 0.1% pimecrolimus ointment) could be used, showing a better safety profile and low side effects, especially in active, edematous CLE of the face. Topical retinoids could be considered as second-line treatment in verrucous LE and other hyperkeratotic lesions of CLE, especially in cases refractory to topical corticosteroids or topical calcineurin inhibitors.
The first-line systemic treatment for all types of CLE includes antimalarials, namely hydroxychloroquine (HCQ), chloroquine (CQ) and quinacrine (Q), with HCQ being the most studied and used agent even in pregnancy and pediatric patients. However, long-term use (i.e., ≥ 5 years) and high-dose HCQ (i.e., > 5 mg/kg/day) are both risk factors for the development of HCQ retinopathy (19). Accordingly, dose should be calculated on body weight with a maximum daily dose of 5 mg/kg of real bodyweight for HCQ and 2.3 mg/kg of real bodyweight for CQ to reduce side effects. However, in contrast with current guidelines, a recent survey demonstrated that about 70% of patients uses a fixed dose of antimalarials independent of the patient’s weight. In both Europe and the USA, HCQ is often prescribed as 200 mg film-coated tablets, while 100 mg HCQ tablets are available in China, not yet approved by the US FDA. The most commonly reported daily dose of HCQ was 400 mg. An inappropriate dose of antimalarials could be one of the reasons for refractory skin manifestations (19). Antimalarials are also burdened by low therapeutic adherence (20–22), especially in younger patients and in patients not convinced of the efficacy of antimalarials in the management of their disease (19). In fact, 17.3% of CLE patients skip HCQ once a week or more often. Non-adherence to HCQ could potentially lower the risk of retinopathy in the individual patient but has been associated with an increased risk of flares and may partly explain cases of refractory CLE. Thus, in case of refractory CLE should be evaluated the adherence and eventually, dosed HCQ blood levels. The need for alternative therapies in refractory CLE has been also emphasized by the limited access to quinacrine that in recent years has restricted its combination with HCQ and CQ.
In case of refractory CLE, Q could be added either to HCQ and CQ with good results, whereas the combination of HCQ and CQ should be avoid because of the risk of irreversible retinopathy. In addition, systemic corticosteroids are recommended as first-line treatment in highly active and/or severe CLE. They should be used for short periods, gradually tapering until withdrawal, to reduce corticosteroids-associated side effects (7–9).
Second- and third-line systemic treatments include immunosuppressants and immunomodulants. Over the last years, increasing knowledges in the pathogenesis of CLE and SLE also led to several new therapeutic options, such as B-cell- or interferon (IFN) α-targeted agents. Herein we reported a review on the current drugs available for refractory CLE.
Immunosuppressants and immunomodulants
Systemic corticosteroids are recommended as first-line treatment in highly active and/or severe CLE. Recommended second and third-line systemic immunosuppressant treatments for CLE include methotrexate (MTX), dapsone, systemic retinoids, mycophenolate mofetil and thalidomide/lenalidomide. Herein, we reported the recommended dose and summarized the evidence of efficacy.
Systemic corticosteroids
Systemic corticosteroids are recommended as first-line treatment in highly active and/or severe CLE, in addition to antimalarials. The usual oral dose of systemic corticosteroids is 0.5–1 mg/kg bodyweight per day for about 2–4 weeks followed by tapering of the dose to a minimum (≤7.5 mg/day) with the aim to discontinue the application. During pregnancy or breastfeeding systemic corticosteroids (prednisone and methylprednisolone) should be given in a dose of not more than 10–15 mg per day (9).
Systemic corticosteroids are generally avoided in CLE patients due to the well-known side effects. However, in addition to antimalarials, they are recommended as first-line treatment in highly active and/or severe CLE (8, 9). Besides being beneficial in association to other therapies that may require time for onset of action, in a prospective, cross-sectional, multicenter study performed by EUSCLE, systemic corticosteroids showed the highest efficacy in comparison with all other systemic drugs used for CLE therapy, providing to be effective in 94.3% of the 413 treated patients. Moreover, systemic corticosteroids were most frequently (in 58.1%) and most successfully (in 96.8%) applied in cases of ACLE, probably due to the frequent association with SLE. The usual oral dose of systemic corticosteroids is 0.5–1 mg/kg bodyweight per day for about 2–4 weeks followed by tapering of the dose to a minimum (≤7.5 mg/day) with the aim to discontinue the application to avoid side-effects. In fact, LE patients are particularly susceptible to the side effects of steroids, as they are at increased risk of developing avascular necrosis at baseline (23). The continuation of treatment with antimalarials or other corticosteroids-sparing agents is recommended during the tapering and after discontinuation of systemic corticosteroids. Moreover, to reduce the risk of corticosteroids-associated side-effects, it is recommended to avoid long-term maintenance treatment with corticosteroids in CLE patients without systemic involvement. Systemic corticosteroids are also administered in association to rituximab (2 × 1,000 mg/m2 IV rituximab in combination with 100 mg IV methylprednisolone at an interval of 2 weeks) in patients resistant to other therapeutic agents, such as antimalarials, thalidomide, immunosuppressive drugs, and high-dose of intravenous immune-globulin (IVIg) (24).
Methotrexate
MTX, up to 20 mg per week, is a second-line treatment for refractory CLE, preferably subcutaneously, and in addition to antimalarials. Folic acid at a dose of 5–10 mg/week, the day after MTX injection, should be added to reduce MTX side effects.
In a recent study on 73 patients with antimalarial-refractory CLE, MTX was found to be the second most effective alternative option after thalidomide, with fewer side effects, showing a partial or substantial resolution in 69% of the 19 treated patients (25).
In a retrospective study, 10 of the 12 analyzed patients with CLE receiving weekly administrations of 10–25 mg MTX showed significant improvements of their skin lesions within 6 weeks (26).
Another study of 43 patients with CLE, MTX, as both monotherapy and adjunctive therapy, resulted in significant improvement in activity of cutaneous lesions in 98% of patients, especially in SCLE (27). MTX was administered intravenously at initial 15–25 mg/weekly dose, then tapered to 7.5–1 5 mg/weekly in 8 patients and 10–20 mg/weekly in 7 patients. Severe side effects necessitating discontinuation of MTX treatment were recorded in seven patients (16%), solved after MTX discontinuation.
Both studies supported the use of low dose MTX for management in refractory patients.
In a retrospective study comparing MTX with MMF, MTX was successfully administrated in 72% of 18 SCLE patients and 46% of 13 DLE patient measured by CLASI improvement, with side effects reported by 28% of SCLE patients, among which nausea/diarrhea was the most common cause of discontinuation, and by 19% of DLE patients, with increased transaminases as the main cause of withdrawing (28).
Cyclosporine has been used in combination with MTX with good result and allowing lower dosing when used in combination (29).
A randomized controlled trial (RCT) study on 41 SLE patients with skin involvement comparing the efficacy and safety of MTX and CQ showed significant improvement in both groups, with no significant differences, demonstrating that low-dose MTX can be as effective as CQ (30).
Although CLE patients can benefit from MTX treatment, the drug can cause adverse sequelae, including hematologic, pulmonary, gastrointestinal, and hepatic side effects. Therefore, the drug should be administered under careful physician supervision (31).
Dapsone
Dapsone is the first-line treatment for bullous LE and a second-line treatment for refractory CLE, preferably in addition to antimalarials. Low dose treatment (50 mg daily) should be used with an increased to a maximum of 1.5 mg/kg daily based on clinical response and side effects, monitoring the glucose 6-phosphate dehydrogenase (G6PD).
The European League Against Rheumatism (EULAR) recommended dapsone, 100 mg daily, in SLE with skin lesions, especially bullous manifestations, in non-responsive cases or cases requiring high-dose corticosteroids (32, 33).
Concerning CLE, dapsone seems to work especially on SCLE, DLE and lupus erythematosus panniculitis (LEP) (34–36).
Lindskov and Reymann treated 33 DLE patients with dapsone with satisfactory results in 48% of patients (37).
In a retrospective analysis, Klebes et al. analyzed 34 CLE patients treated with dapsone (median dose: 100 mg/day) as monotherapy or combined with antimalarials, for a mean duration of 16 months. Authors reported a complete remission in 18% (n = 6) of the patients and an improvement in 41% cases (n = 14) while in 18% (n = 6) patients the drug was ineffective. The best effect was seen in SCLE patients with either disease remission or improvement in 75% of the patients, similarly to other reports. Dapsone was discontinued in 4 cases due to reversible side effects and in 5 patients due to poor efficacy (38).
Coburn and Shuster treated 11 patients with DLE showing good result in 8 patients (39).
In a study by Ruzicka and Goerz on the effects of dapsone in 7 patients (4 with DLE and 3 with a wide-spread rash of SLE), SLE patients had remission of discoid lesions, oral lesions and urticarial vasculitis. However, 2 patients with SLE and generalized acute skin lesions as well as 1 patient with disseminated DLE remained unresponsive to dapsone (40). With a dapsone dose of 25 mg in combination with 500 mg vitamin C, Ruzicka and Goerz observed healing of DLE.
Successful treatment of LEP with dapsone was also seen in 11 cases. Disease remission was noted in all patients between 1 and 8 weeks (mean 4.6 weeks) (36).
Overall, the risk of dapsone-dependent side effects is very low. Dapsone is not recommended in patients with G6PD deficiency to avoid one of its severe side effects, hemolytic anemia, in these individuals. It is not recommended in individuals carrying the HLA-B*13:01 allele, which is associated to the development of dapsone hypersensitivity syndrome, a fatal side effects of this drug (41).
Mycophenolate mofetil
Mycophenolate mofetil (MMF) is a third-line option for refractory CLE in addition to antimalarials. Recommended starting dose is 500 mg × 2 daily, that can be increased up to 3 gr daily.
Mycophenolic acid (MPA) could be an alternative choice to MMF.
MMF has been shown to be effective in different CLE subtypes, in combination with HCQ and (or) systemic corticosteroids, in small series (28, 42–44).
A prospective, non-randomized, open pilot study assessed the efficacy of mycophenolate sodium, the enteric-coated form of MMF, in 10 patients with SCLE refractory to antimalarial therapy (45). Remarkable results with significant CLASI improvement were achieved with 1.440 mg/day MMF monotherapy for 3 months. No serious side effects were reported. A retrospective analysis of 24 patients with recalcitrant CLE showed some clinical response in all patients and resolution or near resolution of disease activity in 62% of patients (46). The average final dose of MMF was 2.750 mg/day. Therapy was well tolerated and the mean time to initial response was 2.76 months. The beneficial effects of MMF in combination with HQ are highlighted in a recent case series of three patients with recalcitrant CLE. Doses of MMF from 1,000 to 1,500 mg/day were effective within 5.6 weeks (47).
Azathioprine, cyclosporine, cyclophosphamide
Guidelines do not suggest azathioprine, cyclosporine and cyclophosphamide for CLE without systemic involvement, since few data are available in the literature with no control trials to support routine use in CLE (7–9).
Interestingly, azathioprine has proven good results in non-specific cutaneous LE manifestations, especially recalcitrant leukocytoclastic vasculitis (48).
Retinoids
Retinoids are a second-line treatment in selective CLE patients unresponsive to other treatment, especially hyperkeratotic lesions and verrucous LE, preferably in addition to antimalarials. The recommended daily dose of acitretin and isotretinoin in treatment for CLE is 0.2–1.0 mg/kg body weight. It usually takes 2–6 weeks for patients to achieve treatment response.
Retinoids, including acitretin, isotretinoin and alitretinoin, have been used in refractory CLE with satisfactory results.
In a double-blinded RCT, acitretin 50 mg/day was found to be effective as HCQ 400 mg/day, with improvement or clearance of skin lesions in 48% of the patients receiving acitretin and 50% of patients receiving HCQ. However, acitretin was less tolerated (49).
Both isotretinoin and alitretinoin have been used successfully in small case series (50–52).
For verrucous LE and (or) hypertrophic lesions of CLE, sporadic case reports have also shown significant therapeutic effects of either acitretin or isotretinoin (53, 54).
The main clinical side effects associated to retinoids are skin and mucous membrane dryness, gastrointestinal symptoms, muscle weakness and arthralgia. Due to their teratogenic effects, counseling and contraception must be given to women of childbearing age. They may alter liver function and lipid profile, thus regular blood tests are mandatory.
Immunoglobulins
Intravenous immunoglobulins (IVIG) therapy in refractory CLE has response ranging from partial to almost complete resolution of lesions (55, 56). However S2k guidelines do not suggest use of IVIG for CLE due to flare of lesions and side effects documented in various case series (57, 58).
One of the main concerns is the high cost of the treatment, which limits its widespread use.
Fumaric acid esters (monoethylfumarate and dimethylfumarate)
Fumaric acid esters have been successfully used in CLE in small series (59, 60).
A recent open-label phase II study showed an improvement in disease activity in 11 patients receiving monoethylfumarate and dimethylfumarate, but the primary endpoint, corresponding to 50% reduction in RCLASI score, was not achieved (61). Side effects include mainly gastrointestinal symptoms, e.g., abdominal cramping, nausea, and diarrhea.
Thalidomide/lenalidomide/iberdomide
Guidelines recommend thalidomide as second-line treatment for refractory CLE, especially DLE and SCLE, preferably in addition to antimalarials, whereas lenalidomide is not suggested for the treatment of CLE.
Thalidomide
Thalidomide is an immunomodulatory, anti-inflammatory and anti-angiogenic drug, successfully used to treat CLE in severe refractory cases (62, 63). It also shows photoprotective properties, inhibiting UVB-induced keratinocytes apoptosis (64).
The first studies on thalidomide in CLE date back to 1983, when 60 patients with DLE were treated with high dose of the drug (400 mg/day), obtaining a response in 90% of cases. However, relapses after drug withdrawal were developed by nearly all patients, even if less severe (65). Subsequent case series or small sized studies reported similar results with doses of mainly 50–100 mg daily (63, 65–69).
In a Brazilian study on 65 CLE patients, 98.9% patients reported complete or partial improvement with thalidomide 100 mg daily. However, 82% of them had cutaneous relapse and 43.2% patients presented neuropathy symptoms, which limited the use of the drug (70). Similarly, a prospective study on 60 patients with refractory CLE reported a 98% clinical response rate to 100 mg of thalidomide daily, with flares in 70% patients after drug withdrawal (71). This high relapse rate was confirmed in a recent meta-analysis of 21 studies that used thalidomide for the treatment of CLE, showing a pooled response rate of 90% but a high relapse rate of 71%. After cessation of treatment, 16% of patients manifested peripheral neuropathy but only in 4% the symptoms were persistent (72).
A recent Chinese study of 69 patients demonstrated optimal response rate (71%) at 50 mg daily (73). The same dosage was administrated by Frankel et al. in 5 patients with refractory CLE, 4 (80%) of whom showed a partial or total response after 4–8 weeks of treatment (74).
Overall, thalidomide has been used primarily in the treatment of DLE and SCLE with responses in about 98% of cases: Less frequently, ACLE, LEP, LET, or non-specific lesions, such as pyoderma gangrenosum, obtained remission under thalidomide treatment, with response rate of 50%. None of the previous studies used CLASI (63). It seems that relapses generally occurred between 4 and 8 weeks after drug interruption, but all cases responded to drug reintroduction (72). The rate of relapse after thalidomide withdrawal was 71% compared with 34% with a maintenance dose. DLE forms tended to relapse most often and required a long-term maintenance dose of thalidomide while SCLE forms showed a sustained remission after withdrawal (63).
The main limitation of thalidomide in all the studies were severe side effects, especially peripheral polyneuropathy, thromboembolic events and teratogenicity (75, 76). According to meta-analyses, 24% of patients developed side effects with the need to discontinue the drug, including 16% patients with peripheral neuropathy and 2% with thromboembolic events (72).
Peripheral polyneuropathy may occur early during the first 4 weeks of treatment and is not always reversible even after the withdrawal of the drug. Low maintenance thalidomide-dose (50 mg/day) could reduce the risk of this adverse event.
In a retrospective study of 139 CLE patients, thromboembolic events were found in 8 cases. The risk was higher for patients with a history of arterial thrombosis and hypercholesterolemia. Authors recommend a starting dose of 50 mg/day of thalidomide in association with HCQ. As some patients had high anti-phospholipid antibodies (aPL) titers, low-dose aspirin could prevent thromboembolic events.
Another limitation of thalidomide is its high cost, that affects the choice of alternative drug (77).
Lenalidomide
Lenalidomide (LND), a synthetic thalidomide analog, has proved efficient and well-tolerated in small case series of refractory CLE, both in adults and children, even after thalidomide failure, with lower side effects (78–84).
In a recent multicenter retrospective study on 40 CLE patients, mostly with concomitant systemic involvement, LND was found to be effective in 98% of the patients with a 4-point or 20% decrease in CLASI-A and a complete remission in 43% of patients (85). Authors underlined the long-term efficacy of the treatment. A median 10 month-follow-up was performed (range 07–147 months). Asthenia was the most common side effects (23% of cases) and in 12.5% of patients cardiovascular diseases and cancers were reported, leading to drug discontinuation. In another retrospective study on 19 CLE patients, of whom 12 with DLE, oral LND at starting dose of 5 mg daily, associated to an antiaggregant (acetylsalicylic acid or clopidogrel), determined a complete or partial resolution in 12 (63%) and 5 (26.5%) patients, respectively. Adverse reactions appeared in 17% cases and permanent LND withdrawal occurred in 12% of patients (86).
Totally, considering this latter study and the previous literature, 76 CLE patients (66 adults and 10 adolescents) were treated with LND with complete resolution in 88% cases, of whom 53% had a complete remission. Relapses occurred in about 26.4% (range 0–64%), especially upon dosage reduction (87).
Seven small-sized studies reported complete/partial response in all SLE/CLE treated patients with a mean time to response of 3 months. Comparing to thalidomide, LND was better tolerated with no cases of polyneuropathy or worsening of previous thalidomide-induced neuropathy. However, most of these studies did not perform nerve conduction tests. Flare rate varied from 25 to 75% occurring 0.5–10 months after drug withdrawal (87). As for thalidomide, a high teratogenicity risk was reported.
According to current studies, lenalidomide therefore appears as a valuable option in refractory CLE even after failure or limiting toxicity of thalidomide.
Iberdomide
Iberdomide, a thalidomide derivative, may degradate Ikaros (IKZF1) and Aiolos (IKZF3), two transcription factors involved in immune cell development and homeostasis. These molecules are overexpressed in SLE and play a role in B-cell, T-cell and monocyte regulation (86). In a phase IIa study on 42 SLE, iberdomide was efficient in reducing the Physician’s Global Assessment (PGA) and CLASI-A, being a promising therapeutic strategy in CLE (88).
Biologics and small molecules
Targeting plasmacytoid dendritic cells and interferon signaling
Plasmacytoid dendritic cells (pDCs) are a subset of immune cells linking innate and adaptive immunity. They are well-known for being a major source of type I interferon (IFN) in response to viral infections or self-nucleic acids through signaling pathways involving pattern-recognizing receptors (PRR). pDCs have therefore a primary role in the pathogenesis of several autoimmune diseases with IFN-signature, such as lupus erythematosus. However, pDCs’ spectrum of action appears to be much wider since the description of various interactions with T, B and NK cells. In fact, the expression of proinflammatory cytokines and costimulatory molecules enhance plasma cells differentiation, antibody secretion, Tregs and Th17 lymphocytes commitment, NK cells activation and immune cells recruitment (89). Type I IFN and pDCs represent a central paradigm not only in SLE but also in CLE pathogenesis, as highlighted by lesional skin infiltration from pDCs (90). This evidence poses the basis for a potential therapeutic option in targeting IFN and pDCs in CLE.
BIIB059 is a humanized IgG1 monoclonal antibody which binds BDCA2, a pDCs’ specific receptor which inhibits the production of type I IFN. In a recent phase I, randomized, double-blind, placebo-controlled clinical trial, 8 CLE patients were treated with single doses of BIIB059 resulting in reduction in CLASI-A scores, reduced level of IFN-related genes in blood and reduced immune infiltration in skin lesions Doses were reported to range from 0.05 to 20 mg/kg. Most of the adverse events related to the drug were mild to moderate in severity, mainly consisting in upper respiratory tract infection. One treated patient developed herpes zoster on day 141 (91). A phase II trial for the treatment of SLE and CLE is currently ongoing (NCT02847598) (92).
Immunoglobulin-like transcript 7 (ILT7) is a surface molecule selectively expressed by human pDCs. VIB7734 is a monoclonal antibody properly designed to target ILT7 in order to reduce pDCs functions and count. It showed positive preliminary results in depleting circulating and lesional pDCs in CLE patients in phase I trials, with parallel improvement in disease activity and local type I IFN activity.
In two phase I studies in patients with autoimmune diseases, VIB7734 demonstrated an acceptable safety profile, comparable to that of placebo (93). Phase II clinical trial to study the treatment of moderate to severely active CLE (RECAST SLE) is now recruiting. Patients have been divided into three groups with three dosing intervals.
Among the emerging treatments for CLE, the most promising approach is represented by anifrolumab, a fully humanized, IgG1κ monoclonal antibody targeting IFN-α/β/ω receptor (IFNAR) which disrupt signaling pathways of all type I IFNs. Following the preliminary evidence of efficacy, in July 2021 the FDA approved the use of anifrolumab in SLE patients with active disease under standard therapy in USA. Contemporary, several trials investigating the efficacy and safety of the drug are ongoing in Europe and Japan (94).
A phase IIb trial comparing intravenous anifrolumab vs. placebo in SLE patients demonstrated significant improvement of cutaneous involvement in the high IFN gene signature subgroup (95). More recently, results of the second phase III RCT comparing anifrolumab 300 mg vs. placebo showed a statistically significant difference in CLASI response (49 vs. 25%, respectively, p = 0.039) (96). In another phase II study on the efficacy of subcutaneous anifrolumab in SLE with active skin disease, significant reductions in CLASI activity score were observed in anifrolumab groups (97).
Sifalimumab is a human igG1κ monoclonal antibody targeting IFN-α molecule. A phase IIb trial evaluated efficacy and safety of several fixed intravenous dosages in adults with moderate to severe active SLE with inadequate responses to standard-of-care treatments. Three doses’ intervals were administered to the participants (200, 600, 1,200 mg). Although the 1,200 mg dosage provided the most consistent results, no clear sifalimumab dosage effect was observed in the study. Apart from the success in reducing SLE activity, improvements in CLASI score were greater for all sifalimumab dosages compared with placebo, suggesting an interesting option for SLE and CLE. The percentages of patients with at least one adverse event, serious adverse event or adverse event leading to discontinuation were similar across the groups. The most common adverse events were worsening of SLE, urinary tract infections, headaches, upper respiratory tract infections and nasopharyngitis (98).
Besides type-I IFN, other cytokines of the interferon family are involved in CLE pathogenesis (99). Accordingly, IFNγ showed a potential central role since high levels of IFNγ mRNA were found in DLE lesional skin, while immunohistochemical analyses found statistical difference in staining of receptor between DLE skin samples and normal skin (100).
AMG 811 is a human anti-IFNγ antibody (IgG1 isotype) that selectively targets human IFNγ. The activity of AMG 811 was assessed in a phase I RCT comparing AMG 811 therapy with placebo in DLE patients, showing changes in biomarkers associated with IFNγ in the blood and skins of DLE patients. However, these findings did not reflect significant changes in CLASI score. In fact, although a single subcutaneous dose of 180 mg was well tolerated it did not lead to statistically significant improvements in any of the efficacy outcome measures (101).
CLE lesional skin showed an activation pattern of spleen tyrosine kinase (SYK), a key regulator of cell proliferation and inflammatory pathways which was suggested as a promising target for CLE treatment (102). In a double-blind Phase Ib study the maximum applied GSK2646264 dose at any time point was 10 mg/cm2 over 90 cm2 (900 mg cream containing GSK2646264 9 mg). Topical application of the SYK inhibitor GSK2646264 to active chronic and subacute CLE lesions was well tolerated over 28 days of treatment and no new safety concerns were identified. However, the trial failed to demonstrate a change in disease activity, while a modest decrease in IFN-related genes expression was found (103).
The SYK inhibitor lanraplenib (GS-9876), administered at a dosage of 200 mg, has been tested in a phase II trial in parallel with filgotinib 30 mg via oral administration in female patients with moderate-to-severe CLE, showing greater efficacy than placebo while the higher median decrease in CLASI-A was reached in the group treated with filgotinib. Most adverse events were mild or moderate in severity. Two serious adverse events were reported with lanraplenib and one with filgotinib (104).
B cell- targeted therapies
Among B cell-targeted therapy, rituximab and belimumab have been the most studied drug in cutaneous lesions (7–9). The role of B cells in SLE pathogenesis has been well described (105), whereas their role in CLE is still controversial. A recent study by Abernathy-Close et al. identified a B cell gene signature in the skin of DLE patients, highest than in ACLE and SCLE patients and, interestingly, in patients with DLE without associated systemic disease. These data indicate that while type I IFNs are known to contribute to the recruitment and activation of B cells in autoimmune disease (106), they may not be critical drivers in the differential recruitment of B cells observed in DLE skin. Interestingly, patients with skin lesions and positive autoantibodies tend to have a lower B cell enrichment score in the skin. The role of B cell in CCLE has been also evaluated in a study conducted by Jenks et al. They reported that while most of the patients with primary CCLE are more likely to have a B cell independent disease, 38% of them exhibited a highly activated SLE-like B cell profile providing a possible marker of progression to SLE (107).
Rituximab
Dosages commonly used are two 1,000 mg IV administered 2 weeks apart. Among adverse events reported to the FDA, the most common are febrile neutropenia, pyrexia, pneumonia, and anemia. Serious side effects that can lead to death, include infusion-related reactions, severe skin and mouth reactions, Hepatitis B Virus (HBV) reactivation, Progressive Multifocal Leukoencephalopathy (PML).
Rituximab is a monoclonal antibody directed against the CD20 antigen, leading to B cell depletion.
According to current SLE guidelines, in refractory SLE or in case of intolerance/contraindications to standard immunosuppressive agents, rituximab can be introduced (30).
Concerning skin manifestations, in two large RCTs on patients with SLE (EXPLORER and LUNAR trials) rituximab failed (108, 109). However, prospective registry data showed cutaneous improvement in 70% of rituximab-treated patients with a partial or complete remission of mucocutaneous lesions (107). Study findings suggest that rituximab may be effective in treating severe CLE in some patients with systemic disease, especially those with acute and non-specific types (110). Bullous lupus and LEP have also improved after rituximab (111–116).
Recently, Mumford et al. reported the resolution of refractory isolated DLE with rituximab, suggesting a possible role of B-cell even in this subtype of CLE (117).
Thus, rituximab may have efficacy in patients with SLE and severe active CLE; however, outcomes may vary with SCLE and CCLE subtypes and may reflect the variation in co-medications (93). Its use could be considered when treating severe CLE in some patients with systemic disease, especially those with acute and non-specific types.
Belimumab
The recommended dose for SLE and lupus nephritis is 200 mg once weekly, administered subcutaneously, regardless of weight. Therapy should be interrupted after 6 months if no improvement is obtained. Adverse reactions more frequently reported (> 5% of SLE patients) were viral infections of superior respiratory tract, bronchitis and diarrhea.
Belimumab is a monoclonal antibody that reduces B lymphocyte survival by blocking the binding of soluble human B lymphocyte stimulator (BLyS) to its B cell receptors.
It is approved for SLE whereas no clinical trials have formally studied its effect on CLE (32).
The S2K guidelines do not recommend the use of belimumab for CLE (9); on the contrary, Lu et al. suggested belimumab as fourth-line treatment for widespread, refractory CLE lesions in patients with active SLE, especially those who have repeated recurrence of ACLE lesions during tapering of systemic corticosteroids (8). Accordingly, in a post hoc, pooled analysis of two phase III trials on belimumab in SLE (BLISS-52 and BLISS-76) the treatment, in combination with standard therapy, was associated with statistically significant improvement in mucocutaneous manifestations vs. placebo as assessed by both Safety of Estrogens in Lupus Erythematosus National Assessment– Systemic Lupus Erythematosus (SLE) Disease Activity Index (SELENA-SLEDAI) and British Isles Lupus Assessment Group (BILAG) scale (118). CLASI was not validated until 2011 and therefore was not studied in these randomized controlled trials.
Belimumab was associated with significant improvements in maculopapular eruption (mild), alopecia and active discoid lesions (119).
Recently, a study on 67 Italian SLE patients treated with belimumab, including 19 with mucocutaneous involvement, demonstrated a significant reduction of median CLASI activity score at 24 months, from 5 (range 1–14) to 0.5 (0–6) (120).
Vashisht et al. reported a dramatically improvement of median CLASI activity scores [from 17 (range: 9–31) to 3 (range 2–14); (p = 0.043)] in 5 patients with SLE with recalcitrant CLE after belimumab (121).
Dresco et al. also found a significant clinical improvement in 83% out of 7 patients with CLE with or without SLE, based on the CLASI and RCLASI activity score as well as their quality of life (DLQI) (122).
In a multicentric, retrospective observational study on 16 patients with CLE, of whom 13 with concomitant SLE, 50% of cases responded to belimumab, administered intravenously at 10 mg/kg every 2 weeks for 3 doses and then monthly, with a reduction in CLASI score, although an overall statistical improvement was not observed. Authors suggested that belimumab may be beneficial in some patients, mostly those with mild persistent activity and phototypes IV to VI. Interestingly, a clinical response was observed in all the 3 patients with isolated CLE (123). However, to date, the evidence about the effectiveness of belimumab in CLE not associated with SLE is scarce. Only isolated refractory cases of CLE successfully treated with belimumab have been recently reported.
Janus kinase inhibitors
Ruxolitinib or baricitinib (JAK1/JAK2 inhibitors) and tofacitinib (primarily JAK3 inhibitor), have been reported to clear recalcitrant CLE lesions. Commonly reported adverse effects are infections associated with herpes virus (herpes simplex labialis, reactivation or primary infection with varicella zoster virus, VZV), nasopharyngitis, as well as infections of upper respiratory tract and urinary tract. Manifestation of acne and gastrointestinal side effects, such as nausea and diarrhea, have also been observed. For topical applications, acne and pruritus have been described. Furthermore, patients treated with JAK inhibitors should perform strict contraception until at least 1 week after the end of treatment (124).
The Janus kinases (JAKs) are intracellular tyrosine kinases involved in a broad variety of inflammatory cascades participating in the pathogenesis of both SLE and CLE (107). Particularly, interferon-associated JAK activation is thought to play a key role in CLE lesions, since a significant upregulation of JAK signaling in cutaneous lesions was demonstrated (125).
Two studies have described the use of JAK inhibitors in the treatment of CLE, using the SLE Disease Activity Index 2000 as the main end point which is not specific to skin disease (126, 127). Baricitinib showed complete remission of a refractory papulosquamous rash in an SLE patient (128) and complete clearance of subacute CLE and no further progression of the FFA in a patient who was started on baricitinib 4 mg for 2 months, followed by ongoing maintenance therapy with baricitinib 2 mg (129).
Ruxolitinib, at the full dose of 20 mg twice daily, baricitinib and tofacitinib have been trialed as therapeutic options for familial chilblain LE (130–135). Elman et al. also reported successful response to tocilizumab in non-familial refractory chilblain LE (136).
Bonnardeaux and Dutz showed an improvement in CLASI score in 3 patients with different refractory CLE subtypes treated with tofacitinib administered orally at a dosage of 5 mg twice daily (137). Moreover, topical tofacitinib 2% ointment was found to solve recalcitrant periorbital DLE in a case report (138).
Targeting cytokines and their receptors
Ustekinumab
Ustekinumab is a monoclonal antibody targeting IL-12 and IL-23. Although it seems to be effective in SLE, its role in the management of CLE is still debated (139). Few case reports of successful treatment of SCLE and DLE with ustekinumab, administered at a dosage of 45 mg or 90 mg with subcutaneous injection as for psoriasis (140–142) were reported in literature, while in a recent phase II RCT, ustekinumab in addition to standard therapy resulted superior to placebo in SLE patients with a baseline CLASI-A ≥ 4, showing a 50% improvement of CLASI-A in 17/32 (53%) patients under ustekinumab vs. 6/17 (35%) of the placebo group (p = 0.032) (143). However, the extension study involving 24 subjects in ustekinumab group vs. 14 patients under placebo showed > 50% improvement in CLASI-A score in 79 and 100% of the subjects groups, respectively, at week 112 (144). Moreover, some reports of ustekinumab-induced SCLE are available, generating debate over its use in CLE (145, 146).
Low-dose IL-2
In a recent phase II study of 40 SLE Chinese patients receiving a 12-week treatment with 1 million IU subcutaneous IL-2, skin lesions and alopecia improved according to SELENA-SLEDAI and BILAG scores. However, assessment of disease activity with CLASI score was not performed (147, 148).
Conclusion
Current treatment regimens for CLE generally comprise antimalarials, systemic corticosteroids, immunosuppressive and immunomodulant drugs, while cytotoxic agents are reserved for severe cases. However, available drugs are not always effective and side effects may occur following long-term use. Moreover, chronic steroid exposure and wide spectrum immunosuppression are major triggers of organ damage. As the skin greatly contributes to the burden of disease in terms of personal and psychological wellbeing, occupational disability and therefore medical and social costs, the development of new treatment protocols for severe and refractory cases is necessary.
In the last years, research on the pathogenesis of SLE and CLE had improved, and several new biologics and small molecules-based treatments have been proposed with promising results on skin disease. However, the lack of large clinical data and of standardized and homogeneous score to assess disease activity such as CLASI and RCLASI is a major impediment to improve management strategies in CLE.
Therefore, future prospective studies on this field should be proposed, with the contribution of expert dermatologists.
Author contributions
AV concepted the whole work, drafted and submitted the manuscript. AC, EM, CA, VR, WV, and LQ contributed to literature revision, manuscript production, and pictures collection. MC concepted the work and revised carefully the manuscript. All authors contributed to the article and approved the submitted version.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Hejazi EZ, Werth VP. Cutaneous lupus erythematosus: an update on pathogenesis, diagnosis and treatment. Am J Clin Dermatol. (2016) 17:135–46. doi: 10.1007/s40257-016-0173-9
2. Zhou W, Wu H, Zhao M, Lu Q. New insights into the progression from cutaneous lupus to systemic lupus erythematosus. Expert Rev Clin Immunol. (2020) 16:829–37. doi: 10.1080/1744666X.2020.1805316
3. Verdelli A, Coi A, Marzano AV, Antiga E, Cozzani E, Quaglino P, et al. Autoantibody profile and clinical patterns in 619 Italian patients with cutaneous lupus erythematosus. J Eur Acad Dermatol Venereol. (2019) 33:742–52. doi: 10.1111/jdv.15147
4. Fabbri P, Cardinali C, Giomi B, Caproni M. Cutaneous lupus erythematosus: diagnosis and management. Am J Clin Dermatol. (2003) 4:449–65. doi: 10.2165/00128071-200304070-00002
5. Jolly M, Kazmi N, Mikolaitis RA, Sequeira W, Block JA. Validation of the Cutaneous Lupus Disease Area and Severity Index (CLASI) using physician- and patient-assessed health outcome measures. J Am Acad Dermatol. (2013) 68:618–23. doi: 10.1016/j.jaad.2012.08.035
6. Kuhn A, Amler S, Beissert S, Böhm M, Brehler R, Ehrchen J, et al. Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI): a modified outcome instrument for cutaneous lupus erythematosus. Br J Dermatol. (2010) 163:83–92. doi: 10.1111/j.1365-2133.2010.09799.x
7. O’Kane D, McCourt C, Meggitt S, D’Cruz DP, Orteu CH, Benton E, et al. British Association of Dermatologists guidelines for the management of people with cutaneous lupus erythematosus 2021. Br J Dermatol. (2021) 185:1112–23. doi: 10.1111/bjd.20597
8. Lu Q, Long H, Chow S, Hidayat S, Danarti R, Listiawan Y, et al. Guideline for the diagnosis, treatment and long-term management of cutaneous lupus erythematosus. J Autoimmun. (2021) 123:102707. doi: 10.1016/j.jaut.2021.102707
9. Kuhn A, Aberer E, Bata-Csörgõ Z, Caproni M, Dreher A, Frances C, et al. S2k guideline for treatment of cutaneous lupus erythematosus – Guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatology Venereol. (2017) 31:389–404. doi: 10.1111/jdv.14053
10. Kuhn A, Caproni M, Doria A. 15 Management of refractory skin lupus. Lupus Sci Med. (2020) 7:A9–10. doi: 10.1136/lupus-2020-la.15
11. Fairley JL, Oon S, Saracino AM, Nikpour M. Management of cutaneous manifestations of lupus erythematosus: a systematic review. Semin Arthritis Rheum. (2020) 50:95–127. doi: 10.1016/j.semarthrit.2019.07.010
12. Verdelli A, Antiva E, Bonciolini V, Bonciani D, Volpi W, Caproni M. Drug induction in connective tissue diseases. G Ital Dermatol Venereol. (2014) 149:573–80.
13. Cutillas-Marco E, Marquina-Vila A, Grant WB, Vilata-Corell JJ, Morales-Suárez-Varela MM. Vitamin D and cutaneous lupus erythematosus: effect of vitamin D replacement on disease severity. Lupus. (2014) 23:615–23. doi: 10.1177/0961203314522338
14. Gutmark EL, Lin DQ, Bernstein I, Wang SQ, Chong BF. Sunscreen use in patients with cutaneous lupus erythematosus. Br J Dermatol. (2015) 173:831–4. doi: 10.1111/bjd.13736
15. Ahluwalia J, Marsch A. Photosensitivity and photoprotection in patients with lupus erythematosus. Lupus. (2019) 28:697–702. doi: 10.1177/0961203319839486
16. Yang SY, Bernstein I, Lin DQ, Chong BF. Photoprotective habits of patients with cutaneous lupus erythematosus. J Am Acad Dermatol. (2013) 68:944–51. doi: 10.1016/j.jaad.2012.11.016
17. Fayard D, Francès C, Amoura Z, Breillat P, Mathian A, Senet P, et al. Prevalence and factors associated with long-term remission in cutaneous lupus: a longitudinal cohort study of 141 cases. J Am Acad Dermatol. (2022) 87:323–32. doi: 10.1016/j.jaad.2022.03.056
18. Ezra N, Jorizzo J. Hydroxychloroquine and smoking in patients with cutaneous lupus erythematosus. Clin Exp Dermatol. (2012) 37:327–34. doi: 10.1111/j.1365-2230.2011.04266.x
19. Osmani Z, Schrama TJ, Zacouris-Verweij W, Andersen J, Frankel S, Bultink IEM, et al. Hydroxychloroquine treatment in European patients with lupus erythematosus: dosing, retinopathy screening and adherence. Lupus Sci Med. (2021) 8:e000478. doi: 10.1136/lupus-2021-000478
20. Petitdemange A, Felten R, Sibilia J, Martin T, Arnaud L. Prescription strategy of antimalarials in cutaneous and systemic lupus erythematosus: an international survey. Ther Adv Musculoskelet Dis. (2021) 13. doi: 10.1177/1759720X211002595
21. Francès C, Cosnes A, Duhaut P, Zahr N, Soutou B, Ingen-Housz-Oro S, et al. Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study. Arch Dermatol. (2012) 148:479–84. doi: 10.1001/archdermatol.2011.2558
22. Al-Rawi H, Meggitt SJ, Williams FM, Wahie S. Steady-state pharmacokinetics of hydroxychloroquine in patients with cutaneous lupus erythematosus. Lupus. (2018) 27:847–52. doi: 10.1177/0961203317727601
23. Okon LG, Werth VP. Cutaneous lupus erythematosus: diagnosis and treatment. Best Pract Res Clin Rheumatol. (2013) 27:391–404. doi: 10.1016/j.berh.2013.07.008
24. Kuhn A, Ruland V, Bonsmann G. Cutaneous lupus erythematosus: update of therapeutic options part II. J Am Acad Dermatol. (2011) 65:e195–213. doi: 10.1016/j.jaad.2010.06.017
25. Fruchter R, Kurtzman DJB, Patel M, Merola J, Franks AG, Vleugels RA, et al. Characteristics and alternative treatment outcomes of antimalarial-refractory cutaneous lupus erythematosus. JAMA Dermatol. (2017) 153:937–9. doi: 10.1001/jamadermatol.2017.1160
26. Boehm IB, Boehm GA, Bauer R. Management of cutaneous lupus erythematosus with low-dose methotrexate: indication for modulation of inflammatory mechanisms. Rheumatol Int. (1998) 18:59–62. doi: 10.1007/s002960050058
27. Wenzel J, Brähler S, Bauer R, Bieber T, Tüting T. Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. Br J Dermatol. (2005) 153:157–62. doi: 10.1111/j.1365-2133.2005.06552.x
28. Keyes, E, Jobanputra A, Feng R, Grinnell M, Vazquez T, Diaz DA, et al. Comparative responsiveness of cutaneous lupus erythematosus patients to methotrexate and mycophenolate mofetil: a cohort study. J Am Acad Dermatol. (2021). 87:447–8. doi: 10.1016/j.jaad.2021.09.017
29. Klein A, Vogt T, Wenzel SM, Fleck M, Landthaler M. Cyclosporin combined with methotrexate in two patients with recalcitrant subacute cutaneous lupus erythematosus. Australas J Dermatol. (2011) 52:43–7. doi: 10.1111/j.1440-0960.2010.00689.x
30. Islam MN, Hossain M, Haq SA, Alam MN, Ten Klooster PM, Rasker JJ. Efficacy and safety of methotrexate in articular and cutaneous manifestations of systemic lupus erythematosus. Int J Rheum Dis. (2012) 15:62–8. doi: 10.1111/j.1756-185X.2011.01665.x
31. Shah R, Nwannunu CE, Limmer Al, Patel RR, Mui UN, Tyring SK. Brief update on dermatologic uses of methotrexate. Skin Therapy Lett. (2022) 24:5–8.
32. Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. (2019) 78:736–45. doi: 10.1136/annrheumdis-2019-215089
33. de Risi-Pugliese T, Cohen Aubart F, Haroche J, Moguelet P, Grootenboer-Mignot S, Mathian A, et al. Clinical, histological, immunological presentations and outcomes of bullous systemic lupus erythematosus: 10 new cases and a literature review of 118 cases. Semin Arthritis Rheum. (2018) 48:83–9. doi: 10.1016/j.semarthrit.2017.11.003
34. Zampeli E, Moutsopoulos HM. Dapsone: an old drug effective for subacute cutaneous lupus erythematosus. Rheumatology. (2019) 58:920–1.
35. Garza-Mayers AC, McClurkin M, Smith GP. Review of treatment for discoid lupus erythematosus. Dermatol Ther. (2016) 29:274–83.
36. Ujiie H, Shimizu T, Ito M, Arita K, Shimizu H. Lupus erythematosus profundus successfully treated with dapsone: review of the literature. Arch Dermatol. (2006) 142:399–401. doi: 10.1001/archderm.142.3.399
37. Lindskov R, Reymann F. Dapsone in the treatment of cutaneous lupus erythematosus. Dermatologica. (1986) 172:214–7.
38. Klebes M, Wutte N, Aberer E. Dapsone as second-line treatment for cutaneous lupus erythematosus? A retrospective analysis of 34 patients and a review of the literature. Dermatology. (2016) 232:91–6. doi: 10.1159/000441054
40. Ruzicka T, Goerz G. Dapsone in the treatment of lupus erythematosus. Br J Dermatol. (1981) 104:53–7.
41. Zhang F-R, Liu H, Irwanto A, Fu X-A, Li Y, Yu G-Q, et al. HLA-B*13:01 and the dapsone hypersensitivity syndrome. N Engl J Med. (2013) 369:1620–8.
42. Petty AJ, Floyd L, Henderson C, Nicholas MW. Cutaneous lupus erythematosus: progress and challenges. Curr Allergy Asthma Rep. (2020) 20:12.
43. Bardazzi F, Gallo G, Loi C, Misciali C, Patrizi A, Filippini A. Refractory palmo-plantar discoid lupus erythematosus successfully treated with mycophenolate mofetil: unusual localization and literature review. Dermatol Ther. (2021) 34:e14743. doi: 10.1111/dth.14743
44. Gouillon L, Debarbieux S, Berruyer M, Fabien N, Lega JC, Thomas L. Chilblain lupus erythematosus treated successfully with mycophenolate mofetil. Int J Dermatol. (2017) 56:e158–9.
45. Kreuter A, Tomi NS, Weiner SM, Huger M, Altmeyer P, Gambichler T. Mycophenolate sodium for subacute cutaneous lupus erythematosus resistant to standard therapy. Br J Dermatol. (2007) 156:1321–7.
46. Gammon B, Hansen C, Costner MI. Efficacy of mycophenolate mofetil in antimalarial-resistant cutaneous lupus erythematosus. J Am Acad Dermatol. (2011) 65:717–21.e2. doi: 10.1016/j.jaad.2010.08.011
47. Sadlier M, Kirby B, Lally A. Mycophenolate mofetil and hydroxychloroquine: an effective treatment for recalcitrant cutaneous lupus erythematosus. J Am Acad Dermatol. (2012) 66:160–1.
48. Callen JP, Spencer LV, Burruss JB, Holtman J. Azathioprine. An effective, corticosteroid-sparing therapy for patients with recalcitrant cutaneous lupus erythematosus or with recalcitrant cutaneous leukocytoclastic vasculitis. Arch Dermatol. (1991) 127:515–22.
49. Ruzicka T, Sommerburg C, Goerz G, Kind P, Mensing H. Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br J Dermatol. (1992) 127:513–8.
50. Laosakul K, Chiewchanvit S, Chuamanochan M, Tovanabutra N. Acitretin treatment in antimalarial-refractory/intolerant discoid lupus erythematosus: a prospective, open-label, uncontrolled study. Lupus. (2022) 31:575–81. doi: 10.1177/09612033221086878
51. Kuhn A, Patsinakidis N, Luger T. Alitretinoin for cutaneous lupus erythematosus. J Am Acad Dermatol. (2012) 67:e123–6. doi: 10.1016/j.jaad.2011.10.030
52. D’Erme AM, Milanesi N, Difonzo EM, Lotti T, Gola M. Treatment of refractory subacute cutaneous lupus erythematosus with oral isotretinoin: a valid therapeutic option. Dermatol Ther. (2012) 25:281–2. doi: 10.1111/j.1529-8019.2012.01461.x
53. Green SG, Piette WW. Successful treatment of hypertrophic lupus erythematosus with isotretinoin. J Am Acad Dermatol. (1987) 17(2 Pt 2):364–8. doi: 10.1016/s0190-9622(87)70214-x
54. Al-Mutairi N, Rijhwani M, Nour-Eldin O. Hypertrophic lupus erythematosus treated successfully with acitretin as monotherapy. J Dermatol. (2005) 32:482–6. doi: 10.1111/j.1346-8138.2005.tb00785.x
55. Singh H, Naidu G, Sharma A. Intravenous immunoglobulin for the rescue in refractory cutaneous lupus. Indian Dermatol Online J. (2020) 11:1003. doi: 10.4103/idoj.IDOJ_82_20
56. Meiran N, Gotler A. Intravenous immunoglobulin (IVIg) for therapy-resistant cutaneous lupus erythematosus (LE). J Dermatolog Treat. (2004) 15:165–86. doi: 10.1080/09541440042000269
57. Tenti S, Fabbroni M, Mancini V, Russo F, Galeazzi M, Fioravanti A. Intravenous Immunoglobulins as a new opportunity to treat discoid lupus erythematosus: a case report and review of the literature. Autoimmun Rev. (2018) 17:791–5. doi: 10.1016/j.autrev.2018.02.010
58. Ky C, Swasdibutra B, Khademi S, Desai S, Laquer V, Grando SA. Efficacy of intravenous immunoglobulin monotherapy in patients with cutaneous lupus erythematosus: results of proof-of-concept study. Dermatol Rep. (2015) 7:5804. doi: 10.4081/dr.2015.5804
59. Saracino AM, Orteu CH. Severe recalcitrant cutaneous manifestations in systemic lupus erythematosus successfully treated with fumaric acid esters. Br J Dermatol. (2017) 176:472–80. doi: 10.1111/bjd.14698
60. Kuhn A, Landmann A, Bonsmann G. Fumaric acid esters: a new therapeutic option for skin manifestations in lupus erythematosus? Br J Dermatol. (2017) 176:301–2. doi: 10.1111/bjd.14938
61. Kuhn A, Landmann A, Patsinakidis N, Ruland V, Nozinic S, Perusquía Ortiz AM, et al. Fumaric acid ester treatment in cutaneous lupus erythematosus (CLE): a prospective, open-label, phase II pilot study. Lupus. (2016) 25:1357–64. doi: 10.1177/0961203316644335
62. Domingo S, Solé C, Moliné T, Ferrer B, Cortés-Hernández J. Thalidomide exerts anti-inflammatory effects in cutaneous lupus by inhibiting the IRF4/NF-κB and AMPK1/mTOR pathways. Biomedicines. (2021) 9:1857. doi: 10.3390/biomedicines9121857
63. Domingo S, Solé C, Moliné T, Ferrer B, Ordi-Ros J, Cortés-Hernández J. Efficacy of thalidomide in discoid lupus erythematosus: insights into the molecular mechanisms. Dermatology. (2020) 236:467–76. doi: 10.1159/000508672
64. Cummins DL, Gaspari AA. Photoprotection by thalidomide in patients with chronic cutaneous and systemic lupus erythematosus: discordant effects on minimal erythema dose and sunburn cell formation. Br J Dermatol. (2004) 151:458–64. doi: 10.1111/j.1365-2133.2004.06117.x
65. Knop J, Bonsmann G, Happle R, Ludolph A, Matz DR, Mifsud EJ, et al. Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus. Br J Dermatol. (1983) 108:461–6. doi: 10.1111/j.1365-2133.1983.tb04600.x
66. Malara G, Verduci C, Altomonte M, Cuzzola M, Trifirò C, Politi C, et al. Thalidomide and discoid lupus erythematosus: case series and review of literature. Drugs Context. (2022) 11:1–10. doi: 10.7573/dic.2021-9-8
67. Tran B, Yazdani Abyaneh MA, Wu J. Rapid response to treatment with thalidomide in an adolescent with generalized discoid lupus erythematosus. Pediatr Dermatol. (2020) 37:244–5. doi: 10.1111/pde.14067
68. Nutan F, Ortega-Loayza AG. Cutaneous lupus: a brief review of old and new medical therapeutic options. J Investig dermatology Symp Proc. (2017) 18:S64–8. doi: 10.1016/j.jisp.2017.02.001
69. Cuadrado MJ, Karim Y, Sanna G, Smith E, Khamashta MA, Hughes GRV. Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens. Am J Med. (2005) 118:246–50. doi: 10.1016/j.amjmed.2004.04.030
70. Coelho A, Souto MID, Cardoso CRL, Salgado DR, Schmal TR, Cruz MW, et al. Long-term thalidomide use in refractory cutaneous lesions of lupus erythematosus: a 65 series of Brazilian patients. Lupus. (2005) 14:434–9. doi: 10.1191/0961203305lu2124oa
71. Cortés-Hernández J, Torres-Salido M, Castro-Marrero J, Vilardell-Tarres M, Ordi-Ros J. Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome. Br J Dermatol. (2012) 166:616–23.
72. Chasset F, Tounsi T, Cesbron E, Barbaud A, Francès C, Arnaud L. Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus: a systematic review and meta-analysis. J Am Acad Dermatol. (2018) 78:342–50.e4. doi: 10.1016/j.jaad.2017.09.059
73. Wang D, Chen H, Wang S, Zou Y, Li J, Pan J, et al. Thalidomide treatment in cutaneous lesions of systemic lupus erythematosus: a multicenter study in China. Clin Rheumatol. (2016) 35:1521–7. doi: 10.1007/s10067-016-3256-3
74. Frankel HC, Sharon VR, Vleugels RA, Merola JF, Qureshi AA. Lower-dose thalidomide therapy effectively treats cutaneous lupus erythematosus but is limited by neuropathic toxicity. Int J Dermatol. (2013) 52:1407–9. doi: 10.1111/j.1365-4632.2011.05200.x
75. Cesbron E, Bessis D, Jachiet M, Lipsker D, Cordel N, Bouaziz JD, et al. Risk of thromboembolic events in patients treated with thalidomide for cutaneous lupus erythematosus: a multicenter retrospective study. J Am Acad Dermatol. (2018) 79:162–5. doi: 10.1016/j.jaad.2018.02.049
76. Yuki EFN, Soares R, Kupa LVK, Heise CO, Aikawa NE, Arnone M, et al. One-year prospective nerve conduction study of thalidomide neuropathy in lupus erythematosus: Incidence, coasting effect and drug plasma levels. Lupus. (2021) 30:956–64. doi: 10.1177/0961203321998433
77. Rizvi SK, Chong BF. Cost minimization analysis of mainstay treatments in cutaneous lupus erythematous. Dermatol Ther. (2022) 35:e15190. doi: 10.1111/dth.15190
78. Shah A, Albrecht J, Boniila-Martinez Z, Okawa J, Rose M, Rosenbach M, et al. Lenalidomide for the treatment of resistant discoid lupus erythematosus. Arch Dermatol. (2009) 145:303–6. doi: 10.1001/archdermatol.2009.30
79. Braunstein I, Goodman NG, Rosenbach M, Okawa J, Shah A, Krathen M, et al. Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: histologic and circulating leukocyte profile and potential risk of a systemic lupus flare. J Am Acad Dermatol. (2012) 66:571–82. doi: 10.1016/j.jaad.2011.01.015
80. Dalm VASH, Van Hagen PM. Efficacy of lenalidomide in refractory lupus pernio. JAMA Dermatol. (2013) 149:493–4. doi: 10.1001/jamadermatol.2013.1313
81. Okon L, Rosenbach M, Krathen M, Rose M, Propert K, Okawa J, et al. Lenalidomide in treatment-refractory cutaneous lupus erythematosus: efficacy and safety in a 52-week trial. J Am Acad Dermatol. (2014) 70:583–4. doi: 10.1016/j.jaad.2013.11.007
82. Wu EY, Schanberg LE, Wershba EC, Rabinovich CE. Lenalidomide for refractory cutaneous manifestations of pediatric systemic lupus erythematosus. Lupus. (2017) 26:646–9. doi: 10.1177/0961203316676377
83. Kindle SA, Wetter DA, Davis MDP, Pittelkow MR, Sciallis GF. Lenalidomide treatment of cutaneous lupus erythematosus: the mayo clinic experience. Int J Dermatol. (2016) 55:e431–9. doi: 10.1111/ijd.13226
84. Fennira F, Chasset F, Soubrier M, Cordel N, Petit A, Francès C. Lenalidomide for refractory chronic and subacute cutaneous lupus erythematosus: 16 patients. J Am Acad Dermatol. (2016) 74:1248–51. doi: 10.1016/j.jaad.2016.01.054
85. Aitmehdi R, Arnaud L, Francès C, Senet P, Monfort JB, de Risi-Pugliese T, et al. Long-term efficacy and safety outcomes of lenalidomide for cutaneous lupus erythematosus: a multicenter retrospective observational study of 40 patients. J Am Acad Dermatol. (2021) 84:1171–4. doi: 10.1016/j.jaad.2020.11.014
86. Reymann V, Bessis D, Bergeret B, Lipsker D, Du-Thanh A, Terrail N, et al. Efficacy and safety of low-dose oral lenalidomide in refractory cutaneous lupus erythematosus: an open series of 19 cases. J Eur Acad Dermatol Venereol. (2021) 35:e113–5. doi: 10.1111/jdv.16839
87. Yuki EFN, Silva CA, Aikawa NE, Romiti R, Heise CO, Bonfa E, et al. Thalidomide and lenalidomide for refractory systemic/cutaneous lupus erythematosus treatment: a narrative review of literature for clinical practice. J Clin Rheumatol. (2021) 27:248–59. doi: 10.1097/RHU.0000000000001160
88. Furie RA, Hough DR, Gaudy A, Ye Y, Korish S, Delev N, et al. Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study. Lupus Sci Med. (2022) 9:e000581. doi: 10.1136/lupus-2021-000581
89. Swiecki M, Colonna M. The multifaceted biology of plasmacytoid dendritic cells. Nat Rev Immunol. (2015) 15:471–85.
90. Farkas L, Beiske K, Lund-Johansen F, Brandtzaeg P, Jahnsen FL. Plasmacytoid dendritic cells (natural interferon- alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol. (2001) 159:237–43. doi: 10.1016/s0002-9440(10)61689-6
91. Furie R, Werth VP, Merola JF, Stevenson L, Reynolds TL, Naik H, et al. Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus. J Clin Invest. (2019) 129:1359–71. doi: 10.1172/JCI124466
92. Karnell JL, Wu Y, Mittereder N, Smith MA, Gunsior M, Yan L, et al. Depleting plasmacytoid dendritic cells reduces local type I interferon responses and disease activity in patients with cutaneous lupus. Sci Transl Med. (2021) 13:eabf8442. doi: 10.1126/scitranslmed.abf8442
93. Shi H, Gudjonsson JE, Kahlenberg JM. Treatment of cutaneous lupus erythematosus: current approaches and future strategies. Curr Opin Rheumatol. (2020) 32:208–14. doi: 10.1097/BOR.0000000000000704
95. Merrill JT, Furie R, Werth VP, Khamashta M, Drappa J, Wang L, et al. Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus. Lupus Sci Med. (2018) 5:e000284. doi: 10.1136/lupus-2018-000284
96. Furie RA, Morand EF, Bruce IN, Manzi S, Kalunian KC, Vital EM, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol. (2019) 1:e208–19. doi: 10.1002/acr2.11414
97. Bruce I, Nami A, Schwetje E, Pierson M, Chia Y, Kuruvilla D, et al. PK/PD, safety and exploratory efficacy of subcutaneous anifrolumab in SLE: a phase-II study in interferon type I high patients with active skin disease [abstract]. Arthritis Rheumatol. (2019) 71.
98. Khamashta M, Merrill JT, Werth VP, Furie R, Kalunian K, Illei GG, et al. Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. (2016) 75:1909–16. doi: 10.1136/annrheumdis-2015-208562
99. Achtman JC, Werth VP. Pathophysiology of cutaneous lupus erythematosus. Arthritis Res Ther. (2015) 17:182.
100. Toro JR, Finlay D, Dou X, Zheng SC, LeBoit PE, Connolly MK. Detection of type 1 cytokines in discoid lupus erythematosus. Arch Dermatol. (2000) 136:1497–501.
101. Werth VP, Fiorentino D, Sullivan BA, Boedigheimer MJ, Chiu K, Wang C, et al. Brief report: pharmacodynamics, safety, and clinical efficacy of AMG 811, a human anti-interferon-γ antibody, in patients with discoid lupus erythematosus. Arthritis Rheumatol. (2017) 69:1028–34. doi: 10.1002/art.40052
102. Braegelmann C, Hölzel M, Ludbrook V, Dickson M, Turan N, Ferring-Schmitt S, et al. Spleen tyrosine kinase (SYK) is a potential target for the treatment of cutaneous lupus erythematosus patients. Exp Dermatol. (2016) 25:375–9.
103. Walker A, Erwig L, Foster K, Nevin K, Wenzel J, Worm M, et al. Safety, pharmacokinetics and pharmacodynamics of a topical SYK inhibitor in cutaneous lupus erythematosus: a double-blind phase Ib study. Exp Dermatol. (2021) 30:1686–92. doi: 10.1111/exd.14253
104. Zhou X, Yan J, Lu Q, Zhou H, Fan L. The pathogenesis of cutaneous lupus erythematosus: the aberrant distribution and function of different cell types in skin lesions. Scand J Immunol. (2021) 93:e12933. doi: 10.1111/sji.12933
105. Ma K, Du W, Wang X, Yuan S, Cai X, Liu D, et al. Multiple functions of B cells in the pathogenesis of systemic lupus erythematosus. Int J Mol Sci. (2019) 20:6021.
106. Abernathy-Close L, Lazar S, Stannard J, Tsoi LC, Eddy S, Rizvi SM, et al. B cell signatures distinguish cutaneous lupus erythematosus subtypes and the presence of systemic disease activity. Front Immunol. (2021) 12:775353. doi: 10.3389/fimmu.2021.775353
107. Nakayamada S, Tanaka Y. Pathological relevance and treatment perspective of JAK targeting in systemic lupus erythematosus. Expert Rev Clin Immunol. (2022) 18:245–52. doi: 10.1080/1744666X.2022.2040988
108. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. (2010) 62:222–33. doi: 10.1002/art.27233
109. Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum. (2012) 64:1215–26. doi: 10.1002/art.34359
110. Quelhas Da Costa R, Aguirre-Alastuey ME, Isenberg DA, Saracino AM. Assessment of response to B-cell depletion using rituximab in cutaneous lupus erythematosus. JAMA Dermatol. (2018) 154:1432–40.
111. Lowe CD, Brahe CA, Green B, Lam TK, Meyerle JH. Bullous systemic lupus erythematosus successfully treated with rituximab. Cutis. (2019) 103:E5–7.
112. Akpabio AA, Otike-Odibi BI. Severe bullous systemic lupus erythematosus successfully treated with low dose rituximab: a case report from Sub-Saharan Africa. Reumatismo. (2020) 72:115–9. doi: 10.4081/reumatismo.2020.1274
113. Angra D, Roehrs PA, Googe PB, Adamson AS. Pediatric-onset refractory lupus erythematosus panniculitis treated with rituximab. Cutis. (2021) 108:E44–6. doi: 10.12788/cutis.0351
114. Gupta P, Dhanawat A, Mohanty I, Padhan P. Refractory lupus panniculitis treated successfully with rituximab: two cases. Ann Afr Med. (2020) 19:207–10. doi: 10.4103/aam.aam_42_19
115. Correll CK, Miller DD, Maguiness SM. Treatment of childhood-onset lupus erythematosus panniculitis with rituximab. JAMA Dermatol. (2020) 156:566–9. doi: 10.1001/jamadermatol.2019.4984
116. Prieto-Torres L, Alegría-Landa V, Morales-Moya AL, Meriño-Ibarra EE, Ara-Martín M, Requena L. Lupus panniculitis refractory to multiple therapies treated successfully with rituximab: a case report and literature review. Australas J Dermatol. (2018) 59:e159–60. doi: 10.1111/ajd.12685
117. Mumford BP, Assarian Z, Oon S, Chong AH. Refractory discoid lupus erythematosus responds to rituximab. Australas J Dermatol. (2021) 62:e341–3.
118. Schwarting A, Dooley MA, Roth DA, Edwards L, Thompson A, Wilson B. Impact of concomitant medication use on belimumab efficacy and safety in patients with systemic lupus erythematosus. Lupus. (2016) 25:1587–96.
119. Manzi S, Sánchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. (2012) 71:1833–8. doi: 10.1136/annrheumdis-2011-200831
120. Iaccarino L, Bettio S, Reggia R, Zen M, Frassi M, Andreoli L, et al. Effects of belimumab on flare rate and expected damage progression in patients with active systemic lupus erythematosus. Arthritis Care Res. (2017) 69:115–23. doi: 10.1002/acr.22971
121. Vashisht P, Borghoff K, O’Dell JR, Hearth-Holmes M. Belimumab for the treatment of recalcitrant cutaneous lupus. Lupus. (2017) 26:857–64.
122. Dresco F, Puzenat E, Delobeau M, Salard D, Lihoreau T, Pelletier F, et al. [Resistant and progressive cutaneous lupus erythematosus treated with belimumab: a retrospective monocentric study]. Rev Med Interne. (2020) 41:152–9. doi: 10.1016/j.revmed.2019.12.004
123. Salle R, Chasset F, Kottler D, Picard-Dahan C, Jannic A, Mekki N, et al. Belimumab for refractory manifestations of cutaneous lupus: a multicenter, retrospective observational study of 16 patients. J Am Acad Dermatol. (2020) 83:1816–9. doi: 10.1016/j.jaad.2020.05.058
124. Klein B, Treudler R, Simon JC. JAK-inhibitors in dermatology – Small molecules, big impact? Overview of the mechanism of action, previous study results and potential adverse effects. J Dtsch Dermatol Ges. (2022) 20:19–24. doi: 10.1111/ddg.14668
125. Fetter T, Smith P, Guel T, Braegelmann C, Bieber T, Wenzel J. Selective janus kinase 1 inhibition is a promising therapeutic approach for lupus erythematosus skin lesions. Front Immunol. (2020) 11:344. doi: 10.3389/fimmu.2020.00344
126. Wallace DJ, Furie RA, Tanaka Y, Kalunian KC, Mosca M, Petri MA, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. (2018) 392:222–31. doi: 10.1016/S0140-6736(18)31363-1
127. You H, Zhang G, Wang Q, Zhang S, Zhao J, Tian X, et al. Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre. Ann Rheum Dis. (2019) 78:1441–3. doi: 10.1136/annrheumdis-2019-215455
128. Fornaro M, Coladonato L, Venerito V, Cacciapaglia F, Lopalco G, Iannone F. Efficacy of baricitinib on refractory skin papulosquamous rash in a patient with systemic lupus erythematosus. Rheumatology. (2019) 59:1188.
129. Kreuter A, Licciardi-Fernandez MJ, Burmann SN, Paschos A, Michalowitz AL. Baricitinib for recalcitrant subacute cutaneous lupus erythematosus with concomitant frontal fibrosing alopecia. Clin Exp Dermatol. (2022) 47:787–8. doi: 10.1111/ced.15044
130. König N, Fiehn C, Wolf C, Schuster M, Cura Costa E, Tüngler V, et al. Familial chilblain lupus due to a gain-of-function mutation in STING. Ann Rheum Dis. (2017) 76:468–72.
131. Zhang S, Song J, Yang Y, Miao H, Yang L, Liu Y, et al. Type I interferonopathies with novel compound heterozygous TREX1 mutations in two siblings with different symptoms responded to tofacitinib. Pediatr Rheumatol Online J. (2021) 19:1. doi: 10.1186/s12969-020-00490-1
132. Gómez-Arias PJ, Gómez-García F, Hernández-Parada J, Montilla-López AM, Ruano J, Parra-Peralbo E. Efficacy and safety of janus kinase inhibitors in type I interferon-mediated monogenic autoinflammatory disorders: a scoping review. Dermatol Ther. (2021) 11:733–50. doi: 10.1007/s13555-021-00517-9
133. Zimmermann N, Wolf C, Schwenke R, Lüth A, Schmidt F, Engel K, et al. Assessment of clinical response to janus kinase inhibition in patients with familial chilblain lupus and TREX1 mutation. JAMA Dermatol. (2019) 155:342–6. doi: 10.1001/jamadermatol.2018.5077
134. Klaeschen AS, Wolf D, Brossart P, Bieber T, Wenzel J. JAK inhibitor ruxolitinib inhibits the expression of cytokines characteristic of cutaneous lupus erythematosus. Exp Dermatol. (2017) 26:728–30. doi: 10.1111/exd.13253
135. Wenzel J, van Holt N, Maier J, Vonnahme M, Bieber T, Wolf D. JAK1/2 inhibitor ruxolitinib controls a case of chilblain lupus erythematosus. J Invest Dermatol. (2016) 136:1281–3. doi: 10.1016/j.jid.2016.02.015
136. Elman SA, Mazori DR, Merola JF. Tofacitinib for refractory chilblain lupus erythematosus. Int J Dermatol. (2022) 61:e156–7. doi: 10.1111/ijd.15625
137. Bonnardeaux E, Dutz JP. Oral tofacitinib citrate for recalcitrant cutaneous lupus. JAAD Case Rep. (2021) 20:61–4. doi: 10.1016/j.jdcr.2021.09.030
138. Mazori DR, Min MS, Kassamali B, Brichta L, Merola JF, Vleugels RA, et al. Use of tofacitinib, 2%, ointment for periorbital discoid lupus erythematosus. JAMA Dermatol. (2021) 157:880–2. doi: 10.1001/jamadermatol.2021.1198
139. Dahl C, Johansen C, Kragballe K, Braae Olesen A. Ustekinumab in the treatment of refractory chronic cutaneous lupus erythematosus: a case report. Acta Derm Venereol. (2013) 93:368–9. doi: 10.2340/00015555-1467
140. De Souza A, Ali-Shaw T, Strober BE, Franks AG. Successful treatment of subacute lupus erythematosus with ustekinumab. Arch Dermatol. (2011) 147:896–8.
141. Winchester D, Duffin KC, Hansen C. Response to ustekinumab in a patient with both severe psoriasis and hypertrophic cutaneous lupus. Lupus. (2012) 21:1007–10. doi: 10.1177/0961203312441982
142. Mazgaj M, Picard-Dahan C, Deschamps L, Marinho E, Estève E, Descamps V. Successful ustekinumab treatment in a patient with psoriasis and subacute cutaneous lupus erythematosus. Int J Dermatol. (2020) 59:e118–20. doi: 10.1111/ijd.14773
143. van Vollenhoven RF, Hahn BH, Tsokos GC, Wagner CL, Lipsky P, Touma Z, et al. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. Lancet. (2018) 392:1330–9. doi: 10.1016/S0140-6736(18)32167-6
144. van Vollenhoven RF, Hahn BH, Tsokos GC, Lipsky P, Gordon RM, Fei K, et al. Efficacy and safety of ustekinumab in patients with active systemic lupus erythematosus: results of a phase II open-label extension study. J Rheumatol. (2022) 49:380–7. doi: 10.3899/jrheum.210805
145. Guarneri C, Lentini M, Polimeni G, Giuffrida R, Cannavò SP. Ustekinumab-induced drug eruption resembling lymphocytic infiltration (of Jessner-Kanof) and lupus erythematosus tumidus. Br J Clin Pharmacol. (2016) 81:792–4. doi: 10.1111/bcp.12837
146. Tierney E, Kirthi S, Ramsay B, Ahmad K. Ustekinumab-induced subacute cutaneous lupus. JAAD Case Rep. (2019) 5:271–3. doi: 10.1016/j.jdcr.2019.01.015
147. He J, Zhang R, Shao M, Zhao X, Miao M, Chen J, et al. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. (2020) 79:141–9.
Keywords: cutaneous lupus erythematosus (CLE), management, anifrolumab, refractory, belimumab, rituximab, JAK inhibitors, therapy
Citation: Verdelli A, Corrà A, Mariotti EB, Aimo C, Ruffo di Calabria V, Volpi W, Quintarelli L and Caproni M (2022) An update on the management of refractory cutaneous lupus erythematosus. Front. Med. 9:941003. doi: 10.3389/fmed.2022.941003
Received: 10 May 2022; Accepted: 29 August 2022;
Published: 23 September 2022.
Edited by:
Robert Gniadecki, University of Alberta, CanadaReviewed by:
Serena Bergamo, ULSS2 Marca Trevigiana, ItalyPriscila Giavedoni, Hospital Clinic of Barcelona, Spain
Copyright © 2022 Verdelli, Corrà, Mariotti, Aimo, Ruffo di Calabria, Volpi, Quintarelli and Caproni. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Alice Verdelli, YWxpY2UudmVyZGVsbGlAaG90bWFpbC5pdA==